Suchergebnisse - "Cariou, Bertrand"

PubPharm (12)

1

Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia : A Randomized Clinical Trial

enthalten in: JAMA pediatrics | 2024

von Santos, R. | Wiegman, A. | Caprio, S. | +7

2

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

enthalten in: Cardiovascular diabetology | 2020

von Colhoun, H. | Leiter, L. | Müller-Wieland, D. | +8

3

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia : The ODYSSEY DM-DYSLIPIDEMIA randomized trial

enthalten in: Diabetes, obesity & metabolism | 2018

von Ray, K. | Leiter, L. | Müller-Wieland, D. | +9

4

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk : The ODYSSEY DM-INSULIN randomized trial

enthalten in: Diabetes, obesity & metabolism | 2017

von Leiter, L. | Cariou, B. | Müller-Wieland, D. | +9

CommentIn: Ann Transl Med. 2018 Feb;6(3):60. - PMID 29610751

5

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)

enthalten in: The American journal of cardiology | 2017

von El Shahawy, M. | Cannon, C. | Blom, D. | +6

6

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial : lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

enthalten in: Cardiovascular diabetology | 2017

von Müller-Wieland, D. | Leiter, L. | Cariou, B. | +9

CommentIn: Ann Transl Med. 2017 Dec;5(23 ):477. - PMID 29285510

7

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia : Pooled analysis of eight ODYSSEY Phase 3 clinical program trials

enthalten in: International journal of cardiology | 2016

von Farnier, M. | Gaudet, D. | Valcheva, V. | +3

8

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody

enthalten in: Circulation. Cardiovascular genetics | 2015

von Hopkins, P. | Defesche, J. | Fouchier, S. | +39

CommentIn: Circ Cardiovasc Genet. 2015 Dec;8(6):749-51. - PMID 26671969

9

Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels

enthalten in: Clinical therapeutics | 2015

von Roth, E. | Bujas-Bobanovic, M. | Louie, M. | +1

10

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins : the ODYSSEY COMBO II randomized controlled trial

enthalten in: European heart journal | 2015

von Cannon, C. | Cariou, B. | Blom, D. | +106

CommentIn: Eur Heart J. 2015 May 14;36(19):1146-8. - PMID 25827601